Urogen Pharma (NASDAQ:URGN) Receives $31.43 Average PT from Analysts

Urogen Pharma (NASDAQ:URGN) has been assigned a consensus rating of “Buy” from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $31.4286.

Several analysts have recently weighed in on the company. HC Wainwright lowered their target price on Urogen Pharma from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, August 11th. The Goldman Sachs Group set a $16.00 target price on Urogen Pharma and gave the company a “neutral” rating in a research note on Friday, June 13th. Scotiabank restated an “outperform” rating on shares of Urogen Pharma in a research note on Friday, June 13th. Oppenheimer set a $31.00 target price on Urogen Pharma and gave the company a “buy” rating in a research note on Friday, June 13th. Finally, Guggenheim reissued a “buy” rating and set a $30.00 price objective (up from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th.

Insider Buying and Selling at Urogen Pharma

In other news, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $17.69, for a total value of $176,900.00. Following the completion of the transaction, the insider directly owned 148,229 shares of the company’s stock, valued at approximately $2,622,171.01. The trade was a 6.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,522 shares of Urogen Pharma stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $19.14, for a total transaction of $143,971.08. Following the completion of the transaction, the general counsel directly owned 41,492 shares of the company’s stock, valued at $794,156.88. This trade represents a 15.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 27,833 shares of company stock valued at $457,467. 4.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Urogen Pharma by 216.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock valued at $48,227,000 after buying an additional 2,983,368 shares during the period. RTW Investments LP boosted its holdings in shares of Urogen Pharma by 1.3% in the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company’s stock valued at $40,841,000 after buying an additional 47,447 shares during the period. RA Capital Management L.P. acquired a new position in shares of Urogen Pharma in the 1st quarter valued at about $35,461,000. Soleus Capital Management L.P. acquired a new position in shares of Urogen Pharma in the 2nd quarter valued at about $29,934,000. Finally, Vestal Point Capital LP boosted its holdings in shares of Urogen Pharma by 32.1% in the 1st quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company’s stock valued at $23,812,000 after buying an additional 522,957 shares during the period. 91.29% of the stock is owned by institutional investors and hedge funds.

Urogen Pharma Trading Down 1.8%

Shares of URGN stock opened at $19.71 on Wednesday. The company’s fifty day simple moving average is $15.46 and its 200-day simple moving average is $11.65. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $21.01. The company has a market cap of $911.78 million, a PE ratio of -5.94 and a beta of 1.12.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.23). Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. The business had revenue of $24.22 million during the quarter, compared to analysts’ expectations of $23.06 million. Equities research analysts expect that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.